Research on proprotein convertase subtilisin/kexin type 9 (PCSK9) is being conducted to explore its role in various diseases. Studies are investigating the use of PCSK9 inhibitors to manage conditions such as hypercholesterolaemia, particularly in certain patient populations, and to understand the relationship between PCSK9 levels and disease prognosis. The enzyme's involvement in lipid metabolism and its potential links to diseases like liver disease, pancreatic cancer, and diabetes are also being examined.